Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on August 27, 2010, reporting an event that occurred on August 25, 2010. The company is a Delaware corporation headquartered in Rockville, Maryland, focused on developing cell-based therapies.
Key Financial Metrics
This filing is a Current Report regarding a regulatory milestone and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This filing enables the company to initiate a Phase I clinical trial for the treatment of chronic spinal cord injury.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the IND filing. The filing includes standard disclaimers stating that the information is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. No specific financial guidance or detailed risk factors beyond the inherent risks of clinical trials are detailed in this specific report.
Investor Verification Checklist
- Verify the company name is Neuralstem, Inc., as the input metadata incorrectly referenced Palisade Bio, Inc.
- Confirm the status of the FDA review of the IND application for chronic spinal cord injury.
- Review the attached Press Release (Exhibit 99.1) for specific details on the clinical trial design and timeline.
- Check subsequent filings for any updates on the FDA's response to the IND application.